Q2 Results Updates: Piramal Pharma Profit Rises 350%; Pidilite Revenue Rises 5%

Piramal Pharma Q2 Highlights (Consolidated, YoY)

• Revenue up 17.3% to Rs 2,241.75 crore versus Rs 1,911.38 crore.

• Net profit up 350% to Rs 22.59 crore versus Rs 5.02 crore.

• Ebitda up 29% to Rs 341.61 crore versus Rs 265.64 crore.

• Margin at 15.2% versus 13.9%

Sagar Cements Q2 Highlights (Consolidated, YoY)

• Revenue down 19.0% to Rs 475.12 crore versus Rs 586.82 crore.

• Net loss at Rs 56.98 crore versus loss of Rs 10.85 crore.

• Ebitda down 67% to Rs 19.93 crore versus Rs 60.22 crore.

• Margin at 4.2% versus 10.3%.

Pidilite Industries Q2 Highlights (Consolidated, YoY)

• Revenue up 5.2% to Rs 3,234.91 crore versus Rs 3,076.04 crore.

• Net profit up 18% to Rs 540.30 crore versus Rs 458.53 crore.

• Ebitda up 13% to Rs 768.81 crore versus Rs 679.71 crore.

• Margin at 23.8% versus 22.1%.

IIFL Finance Q2 Highlights (Consolidated, YoY)

• Total income rises 1.62% at Rs 2,577 crore versus Rs 2536 crore.

• Net loss at Rs 93 crore versus profit of Rs 526 crore.

Nuvoco Vistas Corporations consolidated cement sales volume stood at 4.2 MMT in the second quarter of financial ear 2025. Consolidated revenue from operations stood at Rs 2,269 crores during the same period.

Source: Press Release